Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
L-Tryptophan

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral

I DEC / 13
Labetalol or its salts I DEC / 13
Lacosamide or its derivatives I DEC / 13
Lactic acid

When recommended for parenteral use as a tissue sclerosing agent.

I DEC / 13
Lactulose III SEP / 98
Lamivudine or its salts I DEC / 13
Lamotrigine or its salts I DEC / 13
Lanadelumab I NOV / 18
Lanreotide or its salts I DEC / 13
Lansoprazole or its salts I DEC / 13
Lanthanum salts

For human use - when sold for the treatment of hyperphosphatemia.

I DEC / 13
Lapatinib or its salts I DEC / 13
Laronidase I DEC / 13
Larotrectinib or its salts I OCT / 19
Ledipasvir or its salts I DEC / 14
Lefamulin or its salts I SEP / 20
Lefetamine, its salts, derivatives and isomers and salts of derivatives and isomersC I JAN / 03
Leflunomide or its salts or derivatives

Including but not limited to teriflunomide. 

I DEC / 13
Lemborexant or its saltsPDL I DEC / 20
Lenalidomide I DEC / 13
Lenvatinib or its salts I AUG / 16
Letermovir or its salts I DEC / 17
Letrozole I DEC / 13
Leucovorin or its salts I DEC / 13
Leuprolide or its salts I DEC / 13
Levallorphane and its salts I SEP / 98
Levamisole or its salts

For human use. 

I DEC / 13
Levargorphane and its salts II SEP / 98
Levetiracetam I DEC / 13
Levobunolol or its salts I DEC / 13
Levocabastine or its salts or derivatives I DEC / 13
Levocarnitine or its salts or derivatives

When sold for the treatment of primary or secondary levocarnitine deficiency.

I DEC / 13
Levodopa or its salts I DEC / 13
Levomilnacipran or its salts I JUN / 15
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
Lidocaine

For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.

I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Lifitegrast or its salts I MAR / 18
Linaclotide or its salts or derivatives I DEC / 13
Linagliptin or its salts or derivatives I DEC / 13
Lincomycin or its salts or derivatives

Including but not limited to: Clindamycin 

I DEC / 18
Lindane II SEP / 98
Linezolid or its salts I DEC / 13
Liothyronine or its salts

For human use. 

I DEC / 13
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its salts I DEC / 13
Lisinopril or its salts or derivatives I DEC / 13
Lithium or its salts I DEC / 13
Lixisenatide or its salts I JUN / 17
Lodoxamide or its salts or derivatives

Including but not limited to Lodoxamide tromethamine.

I DEC / 13
Lomefloxacin or its salts I DEC / 13
Lomitapide or its salts I FEB / 14
Lomustine I DEC / 13
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
Lopinavir I DEC / 13
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorlatinib or its salts I MAR / 19
Losartan or its salts I DEC / 13
Losoxantrone or its salts I DEC / 13
Lotilaner

For veterinary use.

I MAR / 18
Lovastatin

Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.

I DEC / 14
Loxapine or its salts I DEC / 13
Lumacaftor or its salts or derivatives I AUG / 16
Lumiracoxib I DEC / 13
Lurasidone or its salts I DEC / 13
LuspaterceptPDL I DEC / 20
Lutropin alfa I DEC / 13
Lyme Disease vaccine I FEB / 02

75 résultats


Footnotes

  • C - Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
    N - Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
    NR - Drug has not been reviewed by the NDSAC
    PDL - Drug is listed in the Health Canada Prescription Drug List
    TS - Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
    CR - Drug has been recommended for addition to the Controlled Drugs and Substances Act